Pevifoscorvir-sodium, Publications ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
Pevifoscorvir-sodium, Publications Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments
Pevifoscorvir-sodium, Publications Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
Pevifoscorvir-sodium, Publications Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level
Pevifoscorvir-sodium, Publications Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Prevents CCCDNA Formation and HBV DNA Integration in Vitro
Pevifoscorvir-sodium, Publications High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Pevifoscorvir-sodium, Publications ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
Pevifoscorvir-sodium, Publications Rapid, profound and durable antiviral effects in treatment-naïve or currently-not-treated subjects with chronic hepatitis B virus infection that received 300 mg pevifoscorvir sodium monotherapy for 96 weeks
Pevifoscorvir-sodium, Publications A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants